Amitiza (Lubiprostone) Patent Expiration, LOE Window & CMS Spending

Amitiza (Lubiprostone) by Sucampo Americas: FDA Orange Book LOE 2027-10-25, 5 AB generics, $14.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSucampo Americas
FDA Application & PathwayN021908 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-10-25
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$14.9M
2024 Medicare Part D Spend$2.9M
2024 Medicaid Spend$12.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel